- 6-APB
- 6-(2-Aminopropyl)benzofuran
- BenzoFury
Casale, JF. Letter to the editor regarding: Abbreviations for 5- and 6-(2-aminopropyl)-2,3-dihydrobenzofuran vs. 5- and 6-(2-aminopropyl)benzofuran: A clarification of “APB” and “APDB”. Microgram J., 1 Jan 2012, 9 (1), 46. 220 kB. #6-APB
Casale, JF; Hays, PA. The characterization of 6-(2-aminopropyl)benzofuran and differentiation from its 4-, 5-, and 7-positional analogues. Microgram J., 1 Jan 2012, 9 (2), 61–74. 1.7 MB. GC,MS,NMR,IR
Stanczuk, A; Morris, N; Gardner, EA; Kavanagh, PV. Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in Internet purchased products. Drug Test. Anal., 1 Apr 2013, 5 (4), 270–276. 1.3 MB. https://doi.org/10.1002/dta.1451
Iversen, L; Gibbons, S; Treble, R; Setola, V; Huang, X; Roth, BL. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol., 30 Jan 2013, 700 (1–3), 147–151. 490 kB. https://doi.org/10.1016/j.ejphar.2012.12.006
Jebadurai, J; Schifano, F; Deluca, P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (Benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum. Psychopharmacol. Clin. Exp., 1 Jul 2013, 28 (4), 356–364. 612 kB. https://doi.org/10.1002/hup.2302
Welter-Luedeke, J; Maurer, HH. New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems. Ther. Drug Monit., 1 Feb 2016, 38 (1), 4–11. 216 kB. https://doi.org/10.1097/FTD.0000000000000240
Nugteren-van Lonkhuyzen, JJ; van Riel, AJHP; Brunt, TM; Hondebrink, L. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug Alcohol Depend., 1 Dec 2015, 157, 18–27. 483 kB. https://doi.org/10.1016/j.drugalcdep.2015.10.011 #6-APB
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b
Zawilska, JB; Andrzejczak, D. Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug Alcohol Depend., 1 Jan 2015, 157, 1-17. 3.0 MB. https://doi.org/10.1016/j.drugalcdep.2015.09.030
Burns, L; Roxburgh, A; Bruno, R; Van Buskirk, J. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 840-845. 113 kB. https://doi.org/10.1002/dta.1613
King, LA. New phenethylamines in Europe. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 808-818. 472 kB. https://doi.org/10.1002/dta.1570
Hudson, AL; Lalies, MD; Baker, GB; Wells, K; Aitchison, KJ. Ecstasy, legal highs and designer drug use: A Canadian perspective. Drug Science, Policy and Law, 1 Jan 2014, 1, 1-9. 230 kB. https://doi.org/10.1177/2050324513509190
Simmler, LD; Liechti, ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 143-164. 298 kB. https://doi.org/10.1007/164_2018_113
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Shevyrin, V; Shafran, Y. Distinguishing of 2-MAPB and 6-MAPB: Solution of the problem. J. Mass Spectrom., 1 Oct 2017, 52 (10), 633–637. 474 kB. https://doi.org/10.1002/jms.3970 #6-APB MS
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Benzofurans 6-APB
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #6-APB
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #PP-020
Okamoto, K; Akimoto, S; Ando, T; Ikeda, Y; Kurashima, N. Differentiation of regioisomeric analogs of controlled substances using GC-IR. JCCL, 1 Oct 2016, (56), 49–70. 4.5 MB. #6-APB Japanese, English abstract GC,MS,IR
Nishimura, Y; Tanaka, S; Ikeda, H; Yamazaki, Y. Study of method for identifying regioisomers of controlled drugs. JCCL, 1 Dec 2015, (55), 65–85. 707 kB. #6-APB Japanese, English abstract GC,MS,UV
Meyers-Riggs, B. AIRCR jumps the shark. countyourculture, countyourculture: rational exploration of the underground, 30 Dec 2010.
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #C3 LC
Brandt, SD; Walters, HM; Partilla, JS; Blough, BE; Kavanagh, PV; Baumann, MH. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. Psychopharmacology, 1 Sep 2020, 237 (12), 3703-3714. 1.3 MB. https://doi.org/10.1007/s00213-020-05648-z #6-APB
Rudin, D; McCorvy, JD; Glatfelter, GC; Luethi, D; Szöllősi, D; Ljubišić, T; Kavanagh, PV; Dowling, G; Holy, M; Jaentsch, K; Walther, D; Brandt, SD; Stockner, T; Baumann, MH; Halberstadt, AL; Sitte, HH. (2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. Neuropsychopharmacol., 1 Mar 2022, 47 (4), 914-923. 1.5 MB. https://doi.org/10.1038/s41386-021-01221-0 #6-APB